Results 61 to 70 of about 13,549 (163)

Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib [PDF]

, 2016
Glioblastoma multiforme is the most aggressive and lethal tumor of the central nervous system with limited treatment strategies on offer, and as such the identification of effective novel therapeutic agents is paramount.
Shukla, L, Luwor, RB, Harris, NC, Ware, TMB, Morokoff, AP, Areeb, Z, Stylli, SS, Paradiso, L, Shayan, R, Li, B, Kaye, AH   +10 more
core   +1 more source

Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis

, 2022
Drug-induced thrombotic microangiopathies present in similar fashion but have varied pathogenic mechanisms. Carfilzomib is an irreversible proteasome inhibitor.
Hermelin, Daniela, Blackall, Douglas, Eigbire-Molen, Odianosen, Daniela Hermelin, Douglas Blackall, Odianosen Eigbire-Molen   +5 more
core   +2 more sources

An Interpretable Machine‐Learning Framework for Multi‐Endpoint Drug‐Induced Liver Injury Classification: Evaluating the Contribution of Molecular Structure

Advanced Computing, Volume 1, Issue 1, December 2026.
Molecular structure provides a complementary perspective on drug‐induced liver injury. Integrating 801 drugs across five DILI endpoints, our interpretable AI framework reveals endpoint‐dependent structural contributions and links predictive classification with molecular‐level interpretation, highlighting the complex interplay between clinical ...
Priya Kumari, Kunal Roy, Madhulika Gupta
wiley   +1 more source

Carfilzomib-induced pulmonary hypertension with associated right ventricular dysfunction: A case report

SAGE Open Medical Case Reports, 2021
Carfilzomib, a selective proteasome inhibitor, is approved for use in relapsed and refractory multiple myeloma. Its link to left ventricular dysfunction is well established but little is known about its effects on the right ventricle.
Pei-Chun McGregor, Valia Boosalis, Jayashri Aragam   +2 more
doaj   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, Volume 117, Issue 6, Page 1421-1441, December 2026.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome

, 2013
Mantle cell lymphoma (MCL) remains incurable due to its inevitable pattern of relapse after treatment with current existing therapies. However, the promise of a cure for MCL lies in the burgeoning area of novel agents.
Sun, Luhong, Pham, Lan V., Ford, Richard J., Tamayo, Archito T., You, Yun, Liang, Rong, Wang, Michael, Rollo, Alex, Lin, Xin, Newberry, Kate J., Yang, Jing, Qian, Jianfei, Lee, John, Kwak, Larry W., Yi, Qing, Zhang, Liang, Ou, Zhishuo, Zhao, Xiurong, Blonska, Marzenna   +18 more
core   +1 more source

Multi‐Omics Mendelian Randomization Prioritizes Candidate Druggable Genes for Major Depressive Disorder

Genes, Brain and Behavior, Volume 25, Issue 6, December 2026.
A multi‐omics Mendelian randomization framework integrating blood and brain eQTL/pQTL data with FinnGen GWAS identified six druggable genes causally associated with major depressive disorder. Colocalization and phenome‐wide analyses supported shared genetic architecture and safety profiles, highlighting immune‐inflammatory pathways as promising ...
Huijing Zhou, Qiang Liu, Hao Yan, Guixiang Jin, Wei Zhou, Xiaomin Yin, Nai Wang, Minhui Zheng, Haihong Zheng, Yiming Wu   +9 more
wiley   +1 more source

A Case of Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome

Annals of Internal Medicine: Clinical Cases
Atypical hemolytic uremic syndrome (aHUS) is a rare non-Shiga toxin thrombotic microangiopathy caused by uncontrolled activation of the alternative complement pathway.
Kwasi Opare-Addo, Sammudeen Ibrahim, Basilio Addo, Jorge Chancay Rodriguez   +3 more
doaj   +1 more source

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma

Indian Journal of Medical and Paediatric Oncology, 2020
Background: Although with the introduction of novel agents, clinical outcomes have significantly improved in patients of multiple myeloma (MM); however, nearly all relapse, requiring subsequent treatment.
A P Dubey, Sameer Khatri, Sachin Maggo, Nilabh K Singh, Durgesh Sharma   +4 more
doaj   +1 more source

Bispecific antibodies targeting B‐cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directions

Cancer, Volume 132, Issue 22, 15 November 2026.
Abstract Anti‐B cell maturation antigen (BCMA) therapies, including antibody‐drug conjugates, chimeric antigen receptor T cells, and bispecific antibodies (bsAbs), have recently revolutionized the treatment landscape of multiple myeloma. This review outlines the biologic rationale for targeting BCMA and sheds light on the mechanism of action of bsAbs ...
Enrica Manzato, Gloria Cocchetto, Simona Barbato, Michele Puppi, Simone Masci, Elena Zamagni   +5 more
wiley   +1 more source